SCHEMBL5158616

SCHEMBL5158616

CC(S)O[C@@H](C(N)=O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
SLCO1B1 Q9Y6L6 1/20 0.40
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4A P27815 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614426 0.79 LMNA (0.44) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL23036042 0.79 TSHR (0.41) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL9392455 0.77 LMNA (0.46) USP2SLCO1B1LMNAL3MBTL1PDE4A
Mannitol SCHEMBL3725317 0.76 LMNA (0.55) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL1173141 0.75 USP2 (0.37) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL14759689 0.74 USP2 (0.39) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL5807432 0.73 USP2 (0.41) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL11206594 0.72 LMNA (0.50) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL8864832 0.72 TDP1 (0.40) USP2SLCO1B1LMNAL3MBTL1PDE4A
SCHEMBL2678840 0.71 USP2 (0.53) USP2SLCO1B1LMNAL3MBTL1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0607252-A4 METHOD OF TREATING HIV INFECTION. THOENE JESS G (US) 1996-03-13 EP claimed
EP-0607252-A1 METHOD OF TREATING HIV INFECTION THOENE, Jess G. (US) 1994-07-27 EP claimed
WO-1993006832-A1 METHOD OF TREATING HIV INFECTION THOENE JESS G (US) 1993-04-15 WO claimed
US-12569456-B2 Methods for the treatment of cysteamine sensitive disorders THIOGENESIS THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-4659736-A1 HAIR-SHAPE-IMPARTING METHOD Kao Corporation (JP) 2025-12-10 EP disclosed
EP-4534527-A2 METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS Thiogenesis Therapeutics, Inc. (US) 2025-04-09 EP disclosed
EP-3684418-B1 COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS THIOGENESIS THERAPEUTICS INC (US) 2025-02-12 EP disclosed
WO-2024162257-A1 HAIR-SHAPE-IMPARTING METHOD 花王株式会社 2024-08-08 WO disclosed
US-11786491-B2 Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders THIOGENESIS THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20230218571-A1 CYSTEAMINE PRECURSOR COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS THIOGENESIS THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230190683-A1 METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS THIOGENESIS THERAPEUTICS, INC. 2023-06-22 US disclosed
US-6156077-A Hair cosmetic composition comprising an oxyalkylenized xanthan gum KAO CORPORATION (JP) 2000-12-05 US disclosed
US-5958084-A CONSISTS OF AN OXIDATION DYE PRECURSOR, A COUPLER AND AN OXYALKYLENIZED XANTHANE GUM, AND A SALT OF INORGANIC ACID OR ORGANIC ACID KAO CORPORATION (JP) 1999-09-28 US disclosed
EP-0607252-B1 COMPOSITIONS FOR THE TREATMENT OF HIV INFECTION THOENE JESS G (US) 1998-11-25 EP disclosed
EP-0784970-A2 Hair cosmetic composition Kao Corporation (JP) 1997-07-23 EP disclosed
US-5609860-A Curly hair-straightening composition KAO CORPORATION (JP) 1997-03-11 US disclosed
EP-0607252-A4 METHOD OF TREATING HIV INFECTION. THOENE JESS G (US) 1996-03-13 EP disclosed
EP-0658338-A1 Curly hair-straightening composition comprising keratin reducing substances and alcohols KAO CORPORATION (JP) 1995-06-21 EP disclosed
EP-0607252-A1 METHOD OF TREATING HIV INFECTION THOENE, Jess G. (US) 1994-07-27 EP disclosed
WO-1993006832-A1 METHOD OF TREATING HIV INFECTION THOENE JESS G (US) 1993-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12569456-B2 Methods for the treatment of cysteamine sensitive disorders SLC7A11, CTH, SLC19A1 USP2 2853/4885SLCO1B1 969/4885LMNA 2114/4885
US-20230218571-A1 CYSTEAMINE PRECURSOR COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS CBS, CTH, BHMT USP2 358/4885SLCO1B1 931/4885LMNA 4283/4885
US-20230190683-A1 METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS CTH, CBS, SLC19A1 USP2 1315/4885SLCO1B1 128/4885LMNA 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.